The global Tildrakizumab market is expanding as healthcare providers, pharmaceutical companies, and research institutions invest in advanced therapeutic solutions to address the rising incidence of autoimmune diseases and improve patient outcomes. The market was valued at USD 1.2 billion in 2024 and is projected to reach USD 3.8 billion by 2035, growing at a CAGR of 10.2%.
The Tildrakizumab...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek